RT Journal Article SR Electronic T1 Intravenous lipo-prostaglandin E1 administration for patients with acute central retinal artery occlusion JF BMJ Open Ophthalmology JO BMJ Open Ophth FD BMJ Publishing Group Ltd SP e001014 DO 10.1136/bmjophth-2022-001014 VO 7 IS 1 A1 Takafumi Suzuki A1 Ryo Obata A1 Tatsuya Inoue A1 Yoshiki Ueta A1 Keiko Azuma A1 Hideo Tate A1 Kohdai Kitamoto A1 Chisato Otaki A1 Yoshihiro Hashimoto A1 Makoto Aihara A1 Naoko Tachi YR 2022 UL http://bmjophth.bmj.com/content/7/1/e001014.abstract AB Objective This study aimed to investigate the anatomical and functional changes in patients with central retinal artery occlusion (CRAO) (n=21) treated with 10 µg/day intravenous liposomal prostaglandin E1 (lipo-PGE1).Methods and analysis We used best-corrected visual acuity (BCVA), central retinal thickness with spectral domain optical coherence photography, optical intensity ratio (OIR) with imageJ software and retinal vessel diameter with fundus photography as indicators. Data were analysed using Tukey’s multiple comparisons, Wilcoxon test or Spearman’s correlation analysis as appropriate.Results BCVA was significantly improved at 1 month and 3 months after the initial visit (from 2.18±0.60 to 1.54±0.84 and 1.53±0.88, p=0.030 and p=0.027, respectively). The ratio of retinal vein diameter to optic disc diameter increased in the first month (from 0.40%±0.13% to 0.52%±0.16%, p=0.005). In addition, the OIR at the initial visit was significantly correlated with BCVA at 3 months (p=0.006, r=0.58). No severe adverse effects were observed.Conclusion The results showed that visual acuity and retinal vein constriction improved after lipo-PGE1 therapy. In addition, the OIR in the initial phase can be an indicator of visual prognosis after treatment with PGE1 in patients with CRAO.Data are available upon reasonable request.